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One of the many alarming discoveries of the late last century was the resurgence 
of tuberculosis (TB), a disease caused by the pathogen Mycobacterium 
tuberculosis. Great concern is also caused by the fact that mycobacteria have 
developed extensive drug resistance over the past decades. The emergence of drug 
resistance is partly due to TB therapy being a very lengthy process, the successful 
completion of which takes at least 6 months, leading to problems of compliance, 
premature termination of therapy and subsequently selection of resistant mutants. 
The long treatment time is associated with the pathogens’ ability to switch into a 
metabolic state referred to as dormancy. In this state the bacteria cease replication 
and develop phenotypic resistance to most of the therapeutic agents in use today. 
All these observations have fuelled renewed efforts to develop novel drugs with 
greater potency and the capability of targeting dormant bacteria. The goal of the 
study described here was to make a contribution to these efforts.  
 Mycobacteria exclusively use menaquinones (MK) in their respiratory 
chain. The fact that humans rely on ubiquinone and do not have the capability to 
synthesize menaquinones renders menaquinone metabolism an attractive drug 
target. We investigate here if menaquinone is essential for bacterial survival 
during dormancy, by inhibiting the translation of genes coding for menaquinone 
synthesizing enzymes, through the experimental use of antisense RNA.  
 To this end, we inserted fragments of eight genes coding for enzymes 
thought to be involved in menaquinone metabolism in the antisense orientation, 
into two sets of plasmids containing two distinct dormancy-specific promoters. 
 VII 
 
These plasmids were introduced into Mycobacterium bovis BCG and the resulting 
bacterial transformants were cultivated under oxygen limiting conditions that 
induce dormancy.  
 Differences between transformants and wild-type, concerning the 
bacteria’s ability to survive hypoxia and synthesize menaquinone, were monitored 
by counting colony forming units (CFU) and measuring levels of menaquinones 
via mass spectrometry (MS).  
 Based on our observations of cell growth, cells transformed with a plasmid 
carrying an antisense fragment of the gene entC were compromised in their ability 
to survive hypoxic conditions. However, an inhibition of menaquinone synthesis 
and concurrent drops in menaquinone levels could not be confirmed by 
preliminary MS analysis.     
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Tuberculosis (TB) is a common and deadly bacterial disease caused by the infectious 
agent Mycobacterium tuberculosis (Mtb). Evidence of tubercular decay recently detected 
in spines of Egyptian mummies impressively illustrates just how long this organism has 
been an unwelcome companion to the human race (32, 59). However, in spite of its long 
history, TB is not a problem of the past, as it has firmly resisted all the great efforts 
humans have undertaken to get rid of this scourge and it is now becoming apparent that, 
after initial success of chemotherapy in the second half of the 20th century, the disease is 
resurging due to rising numbers of HIV infections, neglect of TB prevention programs 
and the emergence of drug resistant strains (23, 57). Today the World Health 
Organization (WHO) estimates that about a third of the world population is infected with 
asymptomatic, latent TB, that 9 million people get infected each year and that 
approximately 2 million die of active TB per year, which makes TB the deadliest 
bacterial infectious disease of our day. High numbers of infections occur all along the 
equator from Africa over the Middle East to Southeast Asia with China and Russia also 
sharing a big part of the global TB burden (Figure 1). Out of all countries affected, South 
Africa displayed the highest incidence of cases and India had the largest number of active 




Figure 1: World TB incidence. Cases per 100,000; Red = >300, orange = 200-300; yellow = 100-200;  
green = 0-100 and grey <50. Data from WHO, 2006 
 
 
1.1.2 The Pathogen 
M. tuberculosis (Mtb) is a slow-growing, rod-shaped, aerobic bacterium that divides 
every 16-20 hours. It belongs to the family of Actinomycetes and is closely related to 
Corynebacteria, Streptomyces and Nocardia. As it has only one outer membrane, Mtb is 
considered to be a Gram-positive bacterium. However, as a result of its lipid rich cell 
wall, it only stains poorly upon performance of Gram staining (35). On the other hand, 
Mtb can be successfully stained after being treated with acidic solutions and hence can be 
classified as acid-fast bacilli (AFB) (35). One closely related species of Mtb of great 
importance to researchers is Mycobacterium bovis, the causative agent of a tuberculous 
disease in cattle. An attenuated strain of M. bovis, named Bacillus Calmette-Guérin 
(BCG), in honour of its developers, was created for the purpose of using it as a vaccine 
against TB. Although widely put to use, its efficacy has always been a matter of much 
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doubt and discussion, since results of studies investigating the protective efficacy of BCG 
vaccination are highly variable and inconsistent. Furthermore there is some evidence that 
revaccination does not improve the protective efficacy and can even cause adverse effects 
(3, 18, 19). Apart from its original role as a vaccine, BCG is cultivated for research 
purposes in numerous laboratories all over the world, to serve as the most relevant non-
pathogenic model organism for in vitro studies in place of M. tuberculosis.  
The knowledge gained about the biology of mycobacteria by conducting research 
on BCG is not restricted to aiding the fight against M. tuberculosis alone. There are 
numerous environmental species of mycobacteria that have been identified as being the 
source of tuberculous diseases in humans such as M. avium and M. fortuitum, which 
opportunistically cause infections in immuno-compromised individuals (12, 54). In 
addition, mycobacterial species are the cause of other major, non-tuberculous diseases 
such as M. leprae, the causative agent of leprosy and M. ulcerans the causative agent of 
the severely neglected disease Buruli Ulcer.  
 
1.1.3 Pathology  
The mycobacteria enter the body through the airways as aerosols expelled by an infected 
individual when coughing or sneezing. When they reach the pulmonary alveoli they 
invade alveolar macrophages and set up a primary focus of infection known as Ghon 
focus (36). Inside the macrophages the bacteria can effectively prevent the fusion of 
phagosome and lysosome thereby evading destruction (2, 31, 48). Chemokines and 
cytokines secreted by the invaded macrophages attract neutrophiles, monocytes, T- and 
B-cells, which then aggregate around the site of infection forming a granuloma, thus 




Figure 2: Early stage granuloma. Macrophages form the centre and inner layer, surrounded by lymphocytes 
               (Picture taken from: “Who put the tubercle in Tuberculosis?”, (41)) 
 
 
Granuloma formation also enables immune cells to communicate more effectively with 
each other (5). In early stages of the immune response macrophages can be activated by 
T-cells, which helps them resist the phagosome maturation arrest and delivers the bacteria 
to an environment with lower pH value. This measure does not achieve effective killing 
but clearly affects the bacteria’s ability to divide (41, 44). In the centre of the granuloma, 
infected macrophages eventually fuse to giant multinucleated cells. During the Delayed 
Type Hypersensitivity (DTH) reaction of the immune system, activated cytolytic T-cells 
kill infected macrophages and their pathogenic cargo leading to destruction of the 
surrounding tissue and necrosis (25). This necrotic tissue can develop into a caseous 
lesion, named thus for its whitish, ‘cheesy’ appearance and smell. Caseous lesions have 
been shown to harbour populations of dormant bacteria that are metabolically virtually 
inactive, yet manage to stay viable over a very long time, possibly even decades (34). 
Ridding patients of these dormant bacteria is one of the major challenges faced by current 
TB treatment for several reasons. For one thing it is difficult for the drugs to enter the 
core of these granuloma in sufficient concentrations, second the bacteria increase the 
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thickness of the cell wall upon entering dormancy protecting them from being targeted by 
agents and finally most drugs currently used in TB chemotherapy were selected for their 
ability to kill actively replicating cells (14, 58).     
 
1.1.4 Treatment 
Current treatment against active TB infections includes administration of the four drugs 
rifampicin (RMP), isoniazide (INH), pyrazinamide (PZA) and ethambutol (EMB) for two 
months, and RMP and INH alone for a further four months. The drugs have to be taken 
daily during the first two months and three times a week for the remaining four months of 
treatment (10). Long duration of treatment is among the biggest problems posed by 
tuberculosis resulting from the tenacity with which the pathogen endures the activity of 
therapeutic agents. 
To ensure patients compliance over the course of the whole six months, WHO has 
started the worldwide introduction of the Direct Observed Therapy Short term (DOTS) 
program in 1995. The core idea is that the treatment has to be surveyed extensively in 
order to ensure the patient’s compliance over the whole course of treatment. Over and 
above this, the program aims at increasing political commitment in the fight against TB 





1.1.5 Drug resistance 
Over the last decades, increasing numbers of drug-resistant strains have arisen all over 
the world. This development is largely due to inadequate treatment, patients not adhering 
to the prescribed treatment regimen, premature termination of therapy or low quality 
medication, all of which may lower the chances of total clearance of infection and set the 
stage for resistant strains to crop up (13, 23). Drug resistance is an especially important 
issue in developing countries, largely owing to the high cost of treatment and the 
infrastructure needed to ensure steady supplies and sufficient surveillance of the patient’s 
compliance (20).  
Multidrug-resistant TB (MDR-TB) is defined as resistance to rifampicin (RMP) and 
isoniazid (INH), the two most effective first line TB drugs. A patient infected with MDR-
TB must receive treatment with alternative, second-line drugs that are less potent, exhibit 
more side-effects than RMP and INH and must be taken for at least 18 months (39). 
Clearly this complication of the already lengthy and difficult treatment of a normal TB 
infection causes even greater inconvenience for the patient and results in even bigger 
problems of compliance. To make matters worse, some strains have developed into 
extensively drug-resistant TB (XDR-TB), which basically is MDR-TB with additional 
resistance to any fluoroquinolone and at least one of the three injectable second-line 
drugs. Cases of XDR-TB have been confirmed all over the world including Central 
Europe (10). For patients infected with such a strain, surgical removal of infected tissue 
often remains the last hope. This desperate situation, brought about by the emergence of 
resistant strains and the low success rate of their treatment, has rekindled the field of TB 
research and fuelled renewed efforts to find novel drug targets. 
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1.2 Dormancy and latent disease 
 
1.2.1 Dormancy induction 
The pathogen’s talent for resisting our pharmaceutical assaults with a certain nonchalance 
stems largely from its ability to go dormant (17). Dormancy is defined as a period of 
suspended development or non-replication and minimal metabolic activity, that allows an 
organism to conserve energy. Mycobacterial dormancy can be triggered by nutrient 
starvation, elevated nitrate levels and oxygen deprivation (14, 26). The focus in this work 
lies on the mechanism of oxygen-deprivation induced dormancy.  
If Mtb resides in the lung, how can it ever run out of oxygen? As has been pointed 
out before, mycobacteria do not just reside freely in the lung, but rather induce the 
formation of highly structured cell aggregates termed granuloma. During granuloma 
formation, more and more immune cells are being recruited to the site of infection and 
pack tightly together. They presumably grow so tight that oxygen cannot freely diffuse to 
the centre of the granuloma anymore. In later stages, the blood vessels retreat depriving 
the inner region of its last means of fresh oxygen supply and leaving the bacteria in an 
environment that grows ever more anaerobic (41). Although mycobacteria are historically 
regarded and classified as obligate aerobes, which is true insofar as they need oxygen in 
order to replicate, this does not mean they cannot survive extended periods of hypoxia. 
Decreasing oxygen levels elicit a primary signal, the nature of which thus far has evaded 
detection, and results in the activation of the two-component signalling system 
DosR/DosS/DosT (8). DosS and DosT code for sensor kinases that autophosphorylate at 
a histidine-residue and then transfer phosphate to an aspartate-residue of the transcription 
factor DosR, which in turn controls expression of the 47-gene dormancy response regulon 
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(40). By orchestrating an orderly transition into dormancy, the regulon enables 
mycobacteria to survive hypoxia, nutrient starvation and drug treatment. Populations of 
these dormant bacteria are thought to be capable of causing recurrence of disease years 
after the initial infection has been cleared.      
 
1.2.2 Mimicking dormancy in vitro: the Wayne model 
The temporal transition from aerobic to anaerobic conditions encountered by the bacteria 
in a granuloma are mimicked in the laboratory using the Wayne dormancy model (50). 
To set up a Wayne experiment, synchronized mycobacterial liquid cultures are distributed 
into airtight tubes, placed on magnetic stirrer platforms at 37°C and subjected to gentle 
stirring, to ensure a homogenous culture and a controlled rate of oxygen consumption. 
This allows the bacteria time to adapt to the changing conditions. As the available oxygen 
is gradually consumed the bacteria progress from exponential growth phase through Non-
Replicating Phase 1 (NRP1) at an oxygen saturation of 1%, into Non-Replicating Phase 2 
(NRP2) or dormancy at an oxygen saturation of 0.06% (Figure 3) (9).  


















Figure 3: Growth curves of Wayne dormant cultures. aer = aerobic; Wayne = dormant  
(A-K. Bendt, personal communication) 




1.3 Energy metabolism during dormancy 
1.3.1 The mycobacterial respiratory chain 
The evident correlation between oxygen deprivation and dormancy induction makes a 
closer look at respiration in mycobacteria worthwhile.  
Respiratory chains in general are made up of fairly immobile protein complexes 
lodged in the membrane, and of mobile quinones that can diffuse along the membrane 
and shuttle electrons from one complex to another. Some of the protein complexes, called 
dehydrogenases, accept electrons from NADH on the inside of the cell and hand them 
over to menaquinones, which in turn deliver the electrons to other protein complexes, the 
oxidases or reductases. In a final step, oxidases pass the electrons on to the terminal 
electron acceptor oxygen on the outside of the cell, whereas reductases use alternative 
electron acceptors like nitrate on the inside of the cell. Several of these protein complexes 
can translocate protons across the membrane while passing on electrons, thereby 
establishing and maintaining a membrane potential (53).     
Mycobacteria possess two known NADH dehydrogenases (NDH 1 and NDH 2) 
and a succinate dehydrogenase (SDH), all of which can feed electrons into the chain 
(Figure 4). NDH1 is a proton-pumping NADH-dehydrogenase, which is down-regulated 
during NRP1, whereas the production of the non-proton pumping NDH2 is increased, 
with the result that the proton motive force is lessened and ATP production reduced, 
indicating a cut in energy requirements (51). The only detectable quinone in 
mycobacteria is menaquinone (MK). Menaquinone acts as a centrepiece, as it can accept 
electrons from NDH1, NDH2 as well as SDH and pass them on to the cytochrome-




Mycobacteria employ two different cytochromes, the aa3-type cytochrome c and the 
cytochrome bd. Both are oxidases that pass on the electrons to the terminal electron 
acceptor oxygen. Cytochrome c is bioenergetically more effective and is used during 
normal growth. Cytochrome bd is less effective but shows higher affinity towards oxygen 
and is therefore upregulated under microaerophilic conditions. Hypoxic conditions also 
induce expression of the Nar operon, which controls genes coding for the nitrate 
reductase (Nar) complex that can use nitrate as an alternative terminal electron acceptor. 
 Despite our knowledge on the mycobacterial respiratory chain under aerobic conditions 
and NRP1, it must be emphasized that the energy metabolism during NRP2 remains a 
poorly understood riddle yet to be unravelled. 
 
 
Figure 4: Mycobacterial respiratory chain (picture taken from: “Tuberculosis- metabolism and respiration 
in the absence of growth”, (9)) 
 
 
1.3.2 A delicate balance? 
One of the hallmarks of dormancy is the metabolic downshift and the concurrent 
reduction of ATP synthesis to only a fraction of what it had been during aerobic growth. 
Since dormant bacteria are much more sensitive than aerobic cells to decoupling of the 
proton gradient by nigericin (Srinivasa Rao, Kevin Pèthe; unpublished results), it can be 
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reasoned that this low level of ATP production is crucial for the maintenance of an 
energized membrane and consequently essential for the bacteria’s survival. The 
remaining metabolic activity in a dormant cell could therefore be likened to a very strict 
diet, a narrow window of opportunity that allows the bacteria to survive under such 
adverse conditions.  
This ‘delicate balance’ might be easily disturbed if pressure is applied at the right 
point. As has been mentioned earlier, it is poorly understood what metabolic activity is 
needed to ensure that the cellular membrane of M . tuberculosis remains energized during 
NRP2. We intend to investigate whether menaquinones play a central role in these 
processes. 
 
1.3.3 Menaquinone (MK) 
 As mentioned in section 1.3.1, quinones constitute the mobile element of the respiratory 















Figure 5: Quinones, electron shuttles of the plasma membrane. Head groups encircled;  
MK = menaquinone, UQ = Ubiquinone  
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Menaquinone consists of an aromatic head group that carries the electrons and an 
isoprenic tail, which reaches into the membrane and can be of varying length to give rise 
to a great number of menaquinone species. The aromatic head group of menaquinone is 
what distinguishes it from UQ (Figure 5). 
Many bacteria employ both types of quinones, whereas mycobacteria possess 
most probably only menaquinone and are thus thought to be dependent on it (56). 
Mammalian cells solely use ubiquinone as an electron carrier and cannot synthesise 
menaquinone de novo. However, mammals still require menaquinone derived from food 
and bacteria in the gut, in order to produce a cofactor involved in carboxylation of 
glutamic acids in enzymes of the coagulation cascade. This carboxylase activity is crucial 
for effective blood clotting and lack of menaquinone can lead to uncontrolled 
haemorrhage. Menaquinone is thus also known as Vitamin K (for the first letter in the 
German word “Koagulation” meaning coagulation).  
Different species of menaquinone are distinguished and numbered according to how 
many isoprene units the backbone is comprised of. According to our mass spectrometry 




1.3.4 Biosynthetic pathway of menaquinone 
The essentiality of menaquinone for mycobacteria and the absence of its synthesis in 
mammalian cells are two major prerequisites of a potential drug target and have sparked 
some research focusing on the involved enzymes. The focus of this study lies on the 
synthesis of the aromatic portion of menaquinone. The synthesis of the specific head 
group of menaquinone involves seven steps catalyzed by seven enzymes (Figure 6) 
encoded by menA, menB, menC, menD, menE, menF (entC) and menG (4). Homologues 
for all these genes characterised in E. coli have been found in mycobacteria except for 
menF.  
The conversion of chorismate to isochorismate presumably performed by the 
enzyme EntC is the first dedicated step in the synthesis of menaquinone in mycobacteria. 
The ORF entC has an entirely different genomic location than all other enzymes involved 
in biosynthesis of menaquinone and is thought to replace the function of the enzyme 
MenF that produces isochorismate for the biosynthesis of menaquinone in plants and 
some bacteria (16). Interestingly entC in mycobacteria is essentially a sequence 
homologue of an isochorismate synthase of the same name found in E. coli. EntC in 
E. coli however produces isochorismate used primarily for the synthesis of the 
siderophore enterobactin (30). Transposon mutagenesis experiments indicated that the 
genes menC, menD, menE and menG (menH in mycobacteria) are all essential for 
survival of M. tuberculosis, whereas menA and menB seem to be dispensable (42). For 
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Figure 6: Menaquinone synthesis in mycobacteria 
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1.3.5 Antisense RNA approach  
To investigate whether inhibition of menaquinone synthesis during dormancy results in 
death of the bacteria, a technique termed antisense RNA inhibition was employed. This 
approach was chosen because knockouts of these genes are probably not viable (42) and 
thus would not allow the investigation of the role of menaquinone synthesis during 
dormancy and its importance for bacterial survival. The expression of antisense RNA on 
the other hand can be conditionally induced after the bacterial culture has reached an 
adequate density. Inhibition is achieved by the antisense RNA strand’s ability to 
hybridize to its mRNA counterpart, thus forming double stranded RNA and inhibiting its 
translation. In order to make the inhibition of translation more efficient, the cloned 
antisense sequences produced in the course of this study are designed to include the 
Shine-Dalgarno (SD) ribosomal recognition site in prokaryotes, a short purine-rich 
sequence of nucleotides (AGGAGG) usually located not more than 10 bp upstream of the 
start codon. 
Several research groups have already successfully applied the antisense RNA 
strategy in mycobacteria (6, 24, 38, 55) However none of the inducible systems 
established by these groups seemed to be suitable for use in dormant bacteria generated in 
the Wayne model. The Hsp 40 promoter is known to be leaky and would possibly impede 
the bacteria’s growth in aerobic conditions. The tetC and the amidase system both require 
the Wayne tubes to be opened in order to add the inducing agents, which could prove to 
be a fairly complicated measure if anaerobic conditions are to be maintained. Moreover, 
tetracycline and amidase could induce a stress response in dormant mycobacteria that 
would influence the outcome of the experiments in an unpredictable manner. For these 
reasons, we instead chose to employ a dormancy inducible system, based on the two 
dormancy-specific promoters NarK2 and Rv2466c
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1.3.6 Dormancy specific promoters NarK2 and Rv2466c 
Two sets of expression vectors were generated carrying two different dormancy-specific 
promoters that were used to control the expression of the antisense-RNA fragment.  
The expression vectors containing the promoter sequences were constructed and 
validated by Srinivasa Rao, NITD. One of these promoters originally controls the 
expression of a nitrite extrusion protein termed NarK2 (Figure 4) and the nitrate reductase 
NarX, which form part of the dormancy regulon induced by the DosS/DosR system (29). 
The promoter of the open reading frame Rv2466cc was shown to be upregulated during 
dormancy in a whole genome microarray study of the M. tuberculosis transcriptome (37). 
The function of the gene encoded by Rv2466cc is unknown.  
Both promoters are active in NRP 1 and NRP 2. However, the NarK2 promoter 
loses some of is activity during NRP 2, whereas the Rv2466cc promoter gains activity in 
NRP2. (Srinivasa Rao, personal communication) 
 
1.3.7 Mass spectrometry analysis 
In this study, lipid extracts of M. bovis BCG cells were analyzed using mass 
spectrometry, in order to detect and quantify levels of menaquinone. Detection of a 
reduction in menaquinone levels in the transformants upon dormancy would support the 
assumption that antisense inhibition of menaquinone synthesis had been successful. 
A mass spectrometry machine (MS) allows the separation of a complex mixture 
of molecules into its components, based on differences in their molecular mass. The 
molecules of a sample are ionized and accelerated towards a detector that generates a 
signal upon impact, the intensity of which corresponds to the relative quantity of 
molecules detected.  
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In this study, two different MS machines were used, a Q-TOF (Time Of Flight) 
and a Q-TRAP. The Q-TOF separates molecules ionized through ESI (Electron Spray 
Ionization) by measuring the time it takes them to cover the distance from the sample 
injector to the sample detector. A molecules time of flight is proportional to its mass. 
Unfortunately, all molecules of the same mass are detected at the same time. To avoid 
this and achieve a better resolution, one can pass the sample through a Liquid 
Chromatography column (LC) before injecting it into the Q-TOF. This measure separates 
the molecules according to their solubility, and molecules of the same weight will be 
injected into the mass spectrometer at different times.  
The Q-TRAP has a very different mode of function. It separates molecules 
according to their quadrupoles. The molecules are ionized by an APCI probe 
(Atmospheric Pressure Chemical Ionization) and injected into a sample chamber all at 
once, where they are held suspended in midair in an electromagnetic beam. An oscillator 
generates an electromagnetic disturbance at ever increasing frequencies and molecules 
whose quadrupoles fall into resonance with the oscillator at a certain frequency will be 
freed from the beam and accelerated to the detector electrode. In order to distinguish 
different molecules of the same weight, the Q-TRAP can make use of a series of separate 
chambers in a process called MRM. After mass separation in the first chamber, molecules 
with the m/z ratio of interest can be fragmented in a second chamber and the resulting 
fragments can then be separated by mass once more in a third chamber  


















2.1 Bacterial strains 
Escherichia coli Top10 (Invitrogen, USA) was used as a host strain for all cloning 
experiments. The Mycobacterium bovis strain used was Bacillus Calmette-Guérin (BCG) 
Pasteur strain, provided by the Novartis Institute of Tropical Diseases (NITD).  
 
2.2 Media and growth conditions 
2.2.1 7H9: Liquid growth media for aerobic mycobacterial cultures 
Liquid Middlebrook 7H9 media for growth of aerobic BCG cultures was prepared by 
dissolving 4.7 g of 7H9 powder (Becton Dickinson, USA) in 900 ml MiliQ filtered water, 
adding 2.5 ml 20% Tween80 (Sigma and Aldrich, USA), 4 ml 50% Glycerol (Fisher, 
USA) and supplementing with 100 ml Difco albumin-dextrose-saline solution (Becton 
Dickinson, USA). The mixture was sterilised by vacuum filtration and incubated at 37°C 
overnight to verify sterility. Sterile 7H9 was stored at 4°C until use. BCG cultures were 
grown in Tissue culture flasks (NUNC, Denmark) in a CO2 incubator at 37°C.  
 
2.2.2 Dubos: Liquid growth media for anaerobic mycobacterial cultures 
Wayne hypoxia experiments were performed in liquid Difco Dubos broth. 1.3 g of Dubos 
powder (Becton Dickinson, USA) was dissolved in 180 ml MiliQ filtered water through 
vigorous stirring for several hours. 20 ml Difco albumin supplement was added. To 
prevent clumping of cells 300 µL 20% Tween80 (Sigma and Aldrich, USA) was added to 
give a final concentration of 0.05%. After filter sterilisation the media was placed at 37°C 




2.2.3 7H11 agar: Solid media for growth of Mycobacteria  
 As solid media for growth of BCG Difco 7H11 was used. The mixture was produced by 
dissolving 21 g 7H11 powder (Becton Dickinson, USA) in 900 ml MiliQ filtered water, 
adding 10 ml 50% Glycerol (Fisher, USA) and autoclaving for 15 minutes at 120°C, after 
which it would be left to cool down to 50°C, so that 100 ml heat sensitive Difco OADC 
(Becton Dickinson, USA) supplement could be added. The final mixture was applied to 
Falcon Petri dishes (Becton Dickinson, USA) using serological pipettes. Kanamycin 
(Sigma and Aldrich, USA) was added to some plates for selection purposes at a 
concentration of 30 µg/ml.  
Plates containing kanamycin (30 µg/ml), ampicillin (30 µg/ml) (Sigma and Aldrich, 
USA) and cycloheximide (100 µg/ml) (Sigma and Aldrich, USA) were produced to deal 
with contamination issues.  
 
2.2.4 LB: Liquid media for E. coli 
E. coli were grown in liquid Difco LB broth. The LB broth was prepared by dissolving 
21 g LB powder in 1 L MiliQ filtered water with repeated boiling and stirring. The 
mixture was autoclaved at 121°C for 15 minutes.  
 
2.2.5 LB agar: Solid media for E. coli and contamination checks 
Difco LB plates were produced by dissolving 41 g of LB Agar powder (Becton 
Dickinson, USA) in 1 L MiliQ filtered water and autoclaving at 121°C for 15 minutes. 
These plates were frequently used to check if BCG pre-cultures and Wayne cultures had 




2.2.6 ImMedia Kan Blue™ : Solid media for growth of transformed E. coli 
Transformed E. coli were streaked out on plates made from ImMedia Kan Blue™ powder 
(Invitrogen, USA). ImMedia Kan Blue™ plates contain 40 mg/ml βGal and 50 µg/ml 
kanamycin. The agar was prepared by following instructions by supplier.  
 
2.3 Plasmids and cloning procedures 
2.3.1 Cloning and expression vectors 
The cloning vector used for amplification and verification of the PCR products was 
TOPO2.1 (Invitrogen, USA). It contains a kanamycin selection marker, EcoR1 restriction 
sites and M13 sequences flanking the Topoisomerase region to simplify analysis of the 
insert. 
The second vector pJEM served as a shuttle and expression vector, due to its 
compatibility with both E. coli and mycobacteria. PJEM carries a kanamycin resistance 
marker. The experiments were conducted with two sets of pJEM plasmids, provided by 
S. Rao NITD, differing in the promoter regions preceding the multiple cloning site. The 
two promoters present in the plasmid constructs are dormancy specific and were derived 




2.3.2 Cloned genes 
Fragments of the genes menA (Rv0534c), menB (Rv0548c), menC (Rv0553), menD 
(Rv0555), menE (Rv0542c), entC/menF (Rv3215) and menH (Rv0558) involved in 
menaquinone synthesis, as well as the gene Rv0560c, encoding a putative quinone 
methyltransferase, were amplified from H37Rv genomic DNA of Mycobacterium 
tuberculosis, provided by S. Rao, by Polymerase Chain Reaction (PCR).  
 
2.3.3 Primer design 
The primers for PRC were designed in such a fashion that the PCR products would 
contain approximately a 100 bp part of the upstream region of each gene including the 
Shine-Dalgarno site and about a third of the coding region of the genes of interest.  
The Shine-Dalgarno sequence allows mRNA to establish contact with the ribosome and 
is crucial for efficient translation. Additionally, two dissimilar restriction sites were 
attached to the forward and reverse primers, respectively.  
For menA amplification, the forward primer contained a Kpn1 site; the reverses 
primer carried a BamH1 site. For all other amplification reactions, forward primers 
carried a Kpn1 site and the reverse primer included an Sph1 site. Restriction sites were 
protected from potential loss of end nucleotides by adding two pyrimidines to the primer 
ends. The genomic sequences were obtained from TubercuList web server and the 




Table 1: Primers used for PCR reactions. Added restriction sites are underlined. 
 
Purpose of primers Forward primer Reverse primer 
Amplification of menA 
(Rv0534c) 
Amplified region:  
-108 ; +452 = 560 bp 
5’ ATGGTACCGTGTCC 
GAATTGACTGTGCG 3’ 
5’ TA GGATCC CCG AAG AAC ACA 
AAC ACC GC 3’ 
Amplification of menB 
(Rv0548c) 
Amplified region:  






Amplification of menC 
(Rv0553) 
Amplified region:  
-112 ; +504 = 616 bp 
5’ AT GGTACCAGTACG 
CGGATATGGTGGTG 3’ 
5’ TAGCATGCACAGGGTTGTTC 
AAGGTATTC 3’  
Amplification of menD 
(Rv0555) 
Amplified region:  





Amplification of menE 
(Rv0542c) 
Amplified region:  





Amplification of entC 
(menF) (Rv3215) 
Amplified region:  






Amplification of menH 
(Rv0558) 
Amplified region:  







Amplified region:  












2.3.4 Polymerase chain reaction 
The reagents used were taken from an Invitrogen HOTSTART PCR kit. A master mix for 
eight reactions à 25 µl was produced by mixing 8 µl H37Rv genomic DNA with 20 µl 
10x PCR buffer, 40 µl BufferQ, 8 µl 25 mM MgCl2, 4 µl 10 mM dNTP mix, 2 µl 
HOTSTART Taq polymerase and adding 102 µl sterile water to fill up to a volume of 
200 µl. After distributing the master mix among eight PCR tubes 1 µl 10 µM Forward 
primer and 1 µl of the corresponding 10 µM reverse primer (Research Biolabs, 
Singapore) were added to each tube. The reaction mixtures were tapped lightly to ensure 
homogeneity, given a quick spin and placed into a T3000 Thermocycler PCR machine 
(Biometra, Germany).  
The PCR program was started off with a 15 minute denaturing step at 95°C.  
One PCR cycle consisted of a DNA melting step at 94°C for 40 seconds, an annealing 
step at 57°C for 40 seconds and a transcription step at 72°C for 2 minutes after which the 
cycle would start anew. After 38 cycles an elongation step was added at 72°C for 7 
minutes during which the Taq-polymerase attaches an adenosine overhang to the 5’ ends 
of the PCR product.  
 
2.3.5 Visualizing DNA  
TAE was used as running buffer and main ingredient for all gels. A 50x stock solution 
was prepared by dissolving 242 g of Tris base (Sigma and Aldrich, USA) in 700 ml 
MiliQ filtered water and adding 100ml 0.5M Ethanoldiaminetetracetate (EDTA) (Sigma 
and Aldrich, USA) at pH8 and 57.1ml glacial acetic acid (Fisher, USA). This mixture 
was filled up to one litre with MiliQ water.  
Amplified DNA and plasmid DNA were loaded on gels made of 1.2% agarose in 
TAE plus 5 µl/100 ml ethidium bromide (Sigma and Aldrich, USA).  
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6x Loading dye was prepared by mixing 1 ml 1%bromophenol 
blue, 1 ml 1% xylene cyanol, 1 ml Tris/HCl at pH 7.5, 2 ml sterile 
water and 5 ml glycerol. As a standard we used the 1 Kb plus DNA 
ladder from Invitrogen, USA (Figure 7). The 1Kb Plus DNA 
ladders are not designed to quantitate DNA samples. The total 
concentration of the ladder is measured via absorbance (before 
mixing with the Ready-to-Load buffer). However, there is not an 
accurate estimation of the mass of each band. Results of gel runs 
were recorded using the UV gel reader Gene Genius Bio Imaging 
System (Syngene, India) and the captured photos were analysed  
   with the computer program GeneSnap also from Syngene. 
 
Figure 7: 1kb plus DNA ladder (Invitrogen, USA) 
 
2.3.6 Ligation into Primary vector 
The cloning method of choice was TOPO TA cloning of Taq-amplified DNA. All 
reagents as well as the plasmid TOPO2.1 were purchased from Invitrogen. TOPO 2.1 is a 
plasmid associated with topoisomerase, which keeps the plasmid open at a site with 
thymine overhangs at both open ends (Figure 8).  
The PCR product is adorned with an adenosine overhang on both ends during the 
elongation step by the Taq-polymerase, and can thus be ligated neatly into TOPO2.1. For 
one ligation reaction we used 1 µl vector plasmid, 1 µl salt mix, 3 µl PCR product and 5 





Figure 8: TOPO 2.1 vector map. (taken from: TOPO cloning brochure online, Invitrogen, USA) 
 
 
2.3.7 Transformation of TOP10 E. coli with TOPO2.1 
Chemically competent TOP10 E. coli were thawed on ice, mixed with the TOPO2.1-
menX constructs and left on ice for 30 minutes, exposed to a 42°C heat shock for 90 
seconds, immediately put back on ice for 2 minutes under addition of 250 µl SOC media 
and allowed to recover for 1 hour at 37°C on a shaking platform. The E. coli cells were 
then streaked out on imMedia Kan blue plates™ (Invitrogen, USA). The TOPO2.1 vector 
plasmid contains a lacZα operon, which is disrupted upon incorporation of DNA 
fragments (Figure 8). As a result of this, bacteria that had been transformed with a 
successfully ligated plasmid will form white colonies and could be easily distinguished 
from blue colonies that had been transformed with empty plasmids. 
Two white colonies of each transformation reaction were picked and incubated for 
one day in 5 ml liquid LB broth containing 50 ug/ml kanamycin. Kanamycin was 




2.3.8 TOPO Plasmid extraction 
The bacteria were centrifuged at 3’000 x g for 10 minutes and the plasmid was extracted 
using the QIAprep miniprep kit (Qiagen, USA). The plasmids were sent to Research 
Biolabs, Singapore, for sequencing to verify fidelity of PCR reactions and quality of 
sequences. The bacterial pellet was resuspended in 250µl Buffer P1 containing RNase A 
and transferred to a microcentrifuge tube. 250 µl Buffer P2 was added and the tube was 
inverted several times to ensure thorough mixing. 350 µl Buffer N3 were added and the 
tubes were inverted immediately to avoid localized precipitation. The tubes were 
centrifuged at 17’900 x g for 10 minutes in a tabletop centrifuge. Supernatant was applied 
to a QIAprep spin column and Centrifuged for 30-60 seconds. the column was washed by 
adding 0.75 ml Buffer PE and centrifuging for 30-60 seconds. The flow through was 
discarded and the column was centrifuged for 1 additional minute to remove residual 
wash buffer. 
The QIAprep column was placed in a 1.5 ml microcentrifuge tube and 30-50 µl EB 
were added. After letting the tube stand for 1 minute the DNA was eluted from the 
membrane by centrifuging for 1 minute. Eluted DNA was either used directly or stored at 
-20°C. 
 
2.3.9 Restriction enzyme double digest 
Enzymes and buffers were purchased from New England Biolabs, USA. The shuttle 
vector pJEM and the cloning vector TOPO2.1 containing the cloned gene were digested 
with two different restriction enzymes. All inserts except menA were digested with Kpn1 
and Sph1. These two enzymes both show sufficient activity in the same buffer and the 
digestion reaction could be performed in one step. To this end 2 µl of 10x buffer 1, 2 µl 
of DNA (pJEM or TOPO), 0.5 µl of each enzyme and 13 µl water were combined in a 
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1.5 ml Eppendorf tube. Shrimp Alkaline Phosphatase (SAP) was added to the pJEM 
digestion reaction to avert religation after a single cut. This was unnecessary for the 
TOPO plasmids, since the inserts would be separated from religated or single cut plasmid 
by electrophoresis. The tubes were lightly tapped several times to ensure mixing and 
placed in a 37°C humidified 5% CO2 incubator for 1 hour or overnight.  
Men A had to be cut with the two enzymes BamH1 and Kpn1, which are not 
compatible in the same buffer. A sequential digest was carried out. First the DNA was cut 
with BamH1 for 1 hour in its specific buffer under addition of Bovine Serum Albumin 
(BSA). Again SAP was added to the reaction containing pJEM. Dialysis was carried out 
on filter membranes floating on de-ionized water in a Petri dish. The digestion reactions 
were placed on the membranes and recovered after 10 minutes. This was followed by 
digestion with Kpn1 as described above.  
 
2.3.10 Gel extraction 
A 5 µl aliquot of all reactions was applied to an agarose gel to separate Inserts from 
cloning vector TOPO and open expression pJEM vector from uncut vector. Bands of 
interest were cut out of the gel and the DNA was extracted using reagents and materials 
from the Qiaquick Gel extraction kit for microcentrifuge by Qiagen. The excised Gel 
fragment was placed in a 1.5 ml Eppendorf tube and weighed. Three volumes of Buffer 
QG equivalent to the weight (100mg ≈ 100 µl) were added. The tube was placed in a 
50°C water bath and frequently vortexed until the gel had completely dissolved. Sample 
was removed from water bath and 1 volume of isopropanol was added. A QIAquick spin 
column was placed in a 2 ml collection tube, the sample was applied and centrifuged at 
17’900 x g for 1 minute. 
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After discarding flow through 0.75 ml of buffer PE were applied and the tube was 
centrifuged for 1 minute to wash the sample. Flow through was discarded and the tube 
was again centrifuged for 1 minute to get rid of any residual PE. The column was placed 
in a fresh 1.5 ml Eppendorf tube.  
To elute bound DNA, 50 µl Elution Buffer (EB) were applied evenly on the 
membrane and the tube was centrifuged for 1 minute. Eluted DNA was stored at -20°C if 
not used immediately.  
 
2.3.11 Ligation into pJEM 
The ligation was performed using the Rapid DNA Ligation Kit purchased from Roche. 
Relative amounts of DNA were estimated judging by the intensity of the bands in the gel 
and the ratio insert/plasmid was adjusted accordingly.  
In a typical reaction 1 µl pJEM vector DNA was mixed with 6 µl insert DNA and 4 µl 
DNA dilution buffer to achieve a final volume of 10 µl, to which 10 µl T4 DNA ligation 
buffer and 1 µl T4 DNA ligase were added. Tubes were tapped to ensure mixing of the 
reagents and the reaction was incubated for 5 minutes at room temperature.   
 
2.3.12 Transformation of TOP10 E. coli with pJEM 
The product of the ligation reaction was either used immediately for transformation into 




2.3.13 pJEM plasmid extraction 
Again, plasmid extraction by miniprep was performed as described above (section 2.3.8). 
The plasmids were sent for sequencing to Research Biolabs pte. ltd. to confirm identity, 
quality and orientation of inserts (Appendix). 
 
2.3.14 Transformation into BCG 
Transformation was achieved by electroporation. 50 ml of exponential growth-phase 
BCG culture at an OD of 0.4-0.6 were pelleted and resuspended in 50 ml warm 0.05% 
Tween 80 to wash away salts. The washing step was repeated twice and finally the 
bacteria were resuspended in 3 ml 0.05% Tween 80 forming a highly concentrated 
bacterial suspension. 250 µl of this thick suspension were transferred to each 0.2 mm 
electrocuvette (Biorad, USA) together with 2-5 µl filter dialysed expression vector. After 
electropulsation the bacteria were mixed with ~2 ml warm 7H9 media and allowed to 
recover for 18 hours at 37°C on a shaking platform. 100 µl and 500 µl aliquots of the 
recovered bacteria were streaked on 7H11 plates containing 30 µl/ml kanamycin and 
incubated for at least 14 days at 37°C. Multiple colonies were scraped off the plates and 
inoculated in 7 ml 7H9 containing 30 µl/ml kanamycin. After 2 days clumps were 
allowed to settle and the supernatant was transferred into a new Flask and diluted with 
fresh 7H9 containing kanamycin. This step was repeated after another two days this time 




2.3.15 Generating seed stocks 
Cultures of transformants at an OD of ~0.5 were used to generate seed stocks. The 
bacteria were concentrated to an OD of 1 and mixed with an equivalent volume of 50% 
glycerol resulting in a bacterial suspension with an OD of 0.5 and a glycerol content of 
25%. This suspension was transferred into cryotubes (Nunc, Denmark) in 1.5 ml aliquots 




2.4 Wayne dormancy model 
BCG were taken from two times passaged aerobic pre-cultures and inoculated in Dubos 
at an OD600 of 0.005. Glass tubes (Wheaton, USA) were prepared by washing and 
placing one magnetic cross stirrer in each tube. Caps were screwed on loosely and the 
tubes were autoclaved. The culture was distributed in 17 ml aliquots into the tubes to 
achieve a head-space ratio of ca.1:3. After screwing the caps on tightly and wrapping 
them with Parafilm to ensure air-tightness, the tubes were placed on Variomag poly 
stirring platforms (Variomag, USA) at 37°C and stirred at 170 rpm. 
Growth of the cultures was monitored by measuring OD600 with a Libra S12 
photospectrometer (Biochrom, UK). Consumption of oxygen was followed by adding 
methylene blue to one tube, a dye that decolorizes under anaerobic conditions. 
Cell samples for preparation of lipid extracts, ATP assays, RNA extracts and plating were 
harvested on day 3, day 5, day 7 day 10 and day 20 for extensive experiments 
 
2.4.1 Plating out bacteria for CFU counts 
At each time point cells for CFU counts were taken from 2 separate Wheaton tubes for 
each type of bacteria. 250 µl aliquots of the cells were transferred into 96-well plates. 
Two dilution series were prepared of each aliquot with a multichannel pipette by 
transferring 25 µl of cells into 225 µl of 7H9 or Dubos media thereby achieving a ten-fold 
dilution. This step was repeated until the desired number of dilutions was obtained.  
Day 0 samples were diluted in three steps resulting in a final dilution of 1/1000 or 10-3.  
Day 3 samples were diluted in four steps resulting in a final dilution of 1/10000 or 10-4.  
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All cells obtained from later time-points were diluted to a final dilution of 1/100000 or 
10-5. The bacteria were plated out on cross plates (Falcon, USA) with four sectors 
allowing four different degrees of dilution to be applied to one single plate.  
50 µl of cells were spread over each sector starting with the highest dilution present.  
When the plates had dried they were covered, stacked, wrapped in Saran plastic wrap to 
retain moisture and placed upside down in a 37°C incubator for at least 14 days.    
 
2.4.2 Lipid extraction with chloroform:methanol 2:1 
The amount of cells harvested for the preparation of one lipid sample corresponded to the 
amount of cells present in one ml of culture at an OD600 of 6 as measured with a cuvette 
of 1 cm width in an Ultrospec 3300pro photospectrometer (Amersham, USA). In order 
estimate the amount of culture needed, the average of the Biochrom OD600 readings had 
to be divided by 1.7, because the Wheaton tubes used in the Wayne assay have a width of 
1.7 cm. The resulting number corresponded to the OD600 measurements in cuvettes of 1 
cm width. The volume of culture per sample was calculated with the simple equation:  
OD desired/OD measured = Volume.  
Since every Wheaton tube contains 17ml of culture, the sample volume was 
divided by 17 so as to find out how many bottles needed to be opened for the generation 
of one sample. Enough culture was harvested to make a set of triplicates whenever 
possible. The appropriate volume of culture was transferred to 50 ml Falcon tubes and the 
cells were spun down at 3’000 x g for 10 minutes. The supernatant was discarded leaving 
7ml of media. After resuspension of the pellet, the culture was transferred to Pyrex glass 
tubes with teflonated caps or solvent resistant FEP tubes (Nalgene). Once again, the cells 
were spun down at 3’000 x g for 10 minutes. Pellet was resuspended in HPLC grade 
chloroform:methanol 2:1 and left on a shaker at 200 rpm overnight at 4°C. At this point, a 
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menaquinone standard (MK4) was added to the organic phase, in order to control for 
variations in lipid quantities resulting from the following extraction procedures 
(preparation of standard refer to section 2.4.3). Breaking of organic and aqueous phases 
was achieved by adding 3 ml of MiliQ filtered H2O to each tube, inverting it six times 
and separating the layers by centrifugation at 3’000 g x 20 minutes. The lower organic 
phase was transferred to 10 ml glass vials with a glass Pasteur pipette. To avoid touching 
the intermediate layer with the pipette tip, the tubes had to be tilted. In order to obtain a 
more complete yield of menaquinones, the remaining cells were subjected to a second 
extraction, by adding 3 ml of pure chloroform, inverting the tubes six times and 
separating the layers through centrifugation at 3’000 x g for 20 minutes. The organic 
fractions of the first and second extraction were pooled and dried under a gentle nitrogen 
stream. For storage the dried lipid films were placed at -20°C.  
 
2.4.3 Preparation of MK4 standard 
The short chain menaquinone MK4 (Sigma) containing only four isoprene units was 
chosen as an internal standard for mass spectrometry, because mycobacteria themselves 
do not produce any detectable amounts of MK4 (Guanghou Shui, personal 
communication). The MK4 stock solution comes at a concentration of 10 mg/ml. A series 
of dilutions with chloroform:methanol 1:1 was performed on ice by a factor of 1000 in 
three steps to a final concentration of 10 µg /ml. Of this 10-3 dilution, 125 µl were added 
to the organic phase of every bacterial sample, so that when the dry lipid samples finally 
were resuspended in 250 µl chloroform:methanol for MS analysis, they had a MK4 
concentration of 5 µg/ml.  
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2.4.4 ATP quantification assay 
The ATP content present in 1 ml of Wayne culture was determined with the 
BactitergloTM (Promega, USA) assay, which makes use of the light producing properties 
of the enzyme Luciferase. The amount of light produced directly depends on the amount 
of ATP present. Samples for ATP quantification assay were taken from the same two 
tubes used for CFU counts for each type of bacteria. 1 ml of culture was placed in an 
Eppendorf tube and centrifuged for 10 minutes at 17’900 x g in a table-top centrifuge. 
The supernatant was removed, the pellets were resuspended in 1 ml PBS by vortexing 
and the tubes were placed in a heat block at 95°C for 10 minutes in order to heat-
inactivate the cells. Samples were stored at -20°C. The ATP quantification assay was 
carried out in a non-transparent 96-well plate. 2 x 50 µl of each sample, as well as three 
different standard dilutions containing known concentrations of ATP, were placed into 
two wells each to obtain duplicate readings.  
When all the samples had been distributed, 50 µl of the BacTiterglo (Promega) 
mix were added to each well using a multichannel pipette, so as to minimize time lapse in 
between the first and the last pipetting event. After an incubation time of 10 minutes in 
the dark, the plate was placed into a plate reader and relative luminescence units (RLU) 









2.5 Mass Spectrometry analysis 
 
2.5.1 HPLC/ESI/MS analysis of polar lipids.  
A Waters XTerra column (1mm x 150mm) was utilized for separation of lipids. 
Chloroform:methanol 1:1 (v/v) with 5% of 300 mM piperidine (final concentration 
15 mM) was used as the mobile phase for isocratic elution. A flow rate of 15 µL/min was 
used for a rapid analysis of lipids (~45 min). The capillary voltage was set at 3.0 kV. The 
sample cone voltage was maintained at 50 V. The column eluent was introduced into the 
standard electrospray source of a Waters Micromass Q-Tof micro mass spectrometer 
operated in the negative ion mode. The mass spectrum was acquired from m/z 400 – 2400 
m/z. 
 
2.5.2 HPLC/APCI/MS analysis of menaquinones.  
The inlet system, an Agilent high throughput liquid chromatography HT1100 system 
(Agilent, USA), consisted of an autosampler and binary pump. Chloroform:methanol 1:1 
(v/v) at a flow rate of 250 µl.min-1 was used as the mobile phase for a run of 2 min. 
Typically, 20 µl of sample was injected for one assay. Analysis of menaquinones was 
performed using multiple reaction monitoring (MRM, Figure 9) transitions of parent ions 
of menaquinone to ions at m/z 187 (the common head group) using an Applied 
Biosystems 4000 Q-Trap mass spectrometer (Applied Biosystems, Foster City, CA) . 
Based on precursor scanning results and HPLC/ESI/QTOF data, MRM transitions of 
856/187, 854/187, 788/187, 786/187, 720/187, 718/187, 652/187, 650/187 and 446/187 
(internal standard) was set for quantitative analysis of menaquinones. LC/MS instrument 
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was operated in positive APCI mode with a vaporizer temperature of 500 ºC, corona 





Figure 9: Sketch of the series of chambers in a Q-TRAP MS.  
The first chamber MS1 achieves the first separation of the sample according to mass.  
Molecules with the m/z value of interest are fed into the second chamber where they get fragmented via 
collision-induced dissociation (CID). Resulting fragments pass into the third chamber MS2 where they 
undergo a second mass-separation step. (E.g.: Menaquinone with nine isoprenic units = MK9) 
 
CID 
 MS1                       MS2 
m/z 786                     m/z 187 




































Seven enzymes termed MenA-MenG (MenH in mycobacteria) are known to be involved 
in menaquinone biosynthesis (4). In order to generate antisense constructs, a fragment of 
each gene consisting of a portion of the upstream region and about a third of the coding 
region was amplified by conventional Polymerase chain reaction (PCR) from H37Rv 
chromosomal DNA (Figure 10, left). Amplification of entC was not successful at first, 
but worked fine after lowering annealing temperature from 57°C to 55°C. 
              
Figure 10: Left: PCR products from left to right; menA, menB, menC, menD, menE, entC (missing), menH  
Right: PCR product of Rv0560c 
 
In addition to the enzymes of the menaquinone biosynthetic pathway, Rv0560c encoding 
a putative ubiqiunol methyltransferase was amplified (Figure 10, right). The product of 
this gene potentially has the ability to replace activity of menH. The GelPilot 100bp Plus 
DNA ladder from QIAGEN used initially showed to be of poor quality (Figure 10, left) 
and was later replaced with the 1kb plus DNA ladder from Invitrogen in subsequent gels 
(see section 2.3.5, Figure 7). Nevertheless the sizes of the fragments, lying between 300 
and 700 bp, could be determined quite accurately. 
500 bp 500 bp 
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All PCR products were readily incorporated into TOPO2.1 plasmids, due to the 
adenosine overhangs added by Taq-polymerase. Sequencing of the inserts revealed the 
sequences to be correct and complete.   
 A restriction double digest was performed using the two enzymes Kpn1/Sph1 for 
the TOPO plasmids carrying the menB-menH and Rv0560c antisense-fragments. The 
menA carrying TOPO plasmid was digested with Kpn1/BamH1 as only exception. The 
recurring pattern formed by the three larger bands (Figure 11, left) is composed of 
plasmid DNA and stems from the circumstance that there is already a Kpn1 and an Sph1 
restriction site present on TOPO2.1. Together with the two restriction sites that had been 
added to the inserts during PCR amplification, this adds up to four points of enzymatic 
attack and the plasmid will therefore be digested into four pieces. The vector plasmid 
pJEM was subjected to the same treatment (Figure 11, right). 
  
Figure 11: Left: Kpn1/Sph1 digest of menX-TOPO cloning vectors. The three big DNA fragments 
represent the plasmid, the small DNA fragment the insert.  
Right: Kpn1/Sph1 digest of pJEM expression vector at ~12kb 
 
The double digest produced DNA fragments with two distinct ends, which allowed for 
inverted ligation of the gene fragments into two sets of pJEM plasmids, differing in the 
promoters inserted upstream of the multiple cloning site (MCS)(Figure 12). These two 
dormancy specific promoters are derived from the genes NarK2 and Rv2466c, both of 





The generation of the two sets of plasmids was performed separately, since the 
expression vector carrying the Rv2466c promoter sequence was still being established 
and was not available from the start.  
After ligation into pJEM, orientation and identity of the inserts were confirmed by 
sequencing. The constructs were found to be correct, with the exception of the intended 
menD-Rv2466cpJEM construct, which had accidentally been ligated to menB. 
Furthermore it was confirmed that the inserts were inverted in relation to the promoters 












Figure 12: Top: Vector map of expression vector. The antisense-fragment (red) was ligated into the MCS. 




















8 Inserts    x 
Rv 2466c 
NarK2 
2 Promoters = 16 constructs 
menA-2466, menB2466... 
Anar, Bnar, Cnar.... 
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3.2 Transformants harbouring empty vectors 
As a negative control, BCG harbouring empty pJEM-NarK2 and empty pJEM-2466 were 
grown in the Wayne dormancy model. No significant differences to WT BCG were 
observed regarding OD600 measurements and CFU counts (Srinivasa Rao, personal 
communication, results not shown).    
 
3.3 Growth of menX-NarK2 transformed BCG  
3.3.1 Growth of menX-NarK2 transformants in Wayne model 
 
Under aerobic conditions, all transformants displayed an OD600-development comparable 
to wild-type BCG (data not shown). A Wayne hypoxia induced dormancy assay was set 
up for each menX-NarK2 transformant except menA-NarK2, since the menA-NarK2 
construct was only completed later together with all the menX-2466 constructs. In this 
preliminary experiment, OD600 measurements were taken over a period of 20 days  
(Figure 13). Comparing the transformants to WT BCG, it was observed that OD600 of all 
transformants developed faster in the first three days than the OD600 of the WT. They 
reached OD-values in the range of 0.11-0.13 on day 3, instead of the expected values 
around 0.7 -0.8. Despite this initial burst of growth, the OD600 values converged around 
day 7 and showed a drop of OD600-gain characteristic to dormancy transition. After 20 
days the bottles were opened to create an aerobic environment, which would allow the 
cells to resuscitate.  
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Figure 13: Growth curves of menX-NarK2 transformants and WT BCG  
 
 The OD600 of these resuscitated tubes were measured over the next 5 days, in order to 
determine if the bacteria resumed replication. It was found that all transformants regained 
growth at the same rate as wild-type cells (Figure 13).  
Growth experiments on solid medium with day 10 transformant cells showed 
bacterial growth comparable in numbers to that of WT cells harvested on day 10. The day 
20 CFU counts of this first experiment are not available, because the 7H11 agar used for 
these Petri dishes had been prepared with old 20%Tween80, which impeded bacterial 
growth and made a reliable count impossible. This led to the decision to omit Tween80 in 




3.3.2 Troubleshooting variations in OD600  
Based on the observation that the OD600 of transformants increased at a faster rate than 
that of the wild-type BCG, all transformants were inoculated in 7H9 media and grown 
under aerobic conditions, in order to investigate if they also grow faster under non-
dormancy inducing conditions than wild-type cells. The observation was confirmed. It 
was speculated that one possible explanation for this observation of accelerated growth 
could be contamination, and indeed when the seed stocks were plated on LB plates all 
seed stocks of transformants were found to contain a few cells of yellow, fast growing 
bacteria, presumably micrococci. In order to rid the NarK2 seed stocks of these 
contaminants, all of them were inoculated in 7H9 liquid media containing cycloheximide, 
ampicillin and kanamycin (CAK). Aliquots of these cultures were plated on 7H11 dishes, 
which had been supplemented with CAK. Resulting colonies were scraped off and 
inoculated in 7H9 containing CAK antibiotic mix for 2 days and then diluted twice with 
fresh culture without antibiotics. Aliquots of these cleared cultures were plated out on LB 
agar and when no growth was generated within three days, it was surmised that the 





3.4 Wayne experiments with entC-NarK2 and menB-NarK2  
3.4.1 Growth of entC-NarK2 and menB-NarK2 in Wayne model 
Following this preliminary growth experiment, another smaller scale experiment was set 
up, restricted to just the two constructs Bnar (menB-NarK2) and EntCnar (entC-NarK2). 
This was done to minimize the possibility of errors and in response to logistic problems 
encountered due to restricted numbers of stirring platforms.  
OD600 (Figure 14) was measured and the bacteria were plated on 7H11 agar for 
CFU counts (Figure 15, Figure 16) and on LB as a control for contamination. 





















3.4.2 Troubleshooting variations in OD600 of wild-type cells 
In this follow-up experiment, after performing all the decontamination measures 
described in section 3.3.2, the transformants grew to an average OD600 of 0.07 within the 
first three days, but now the wild-type cells suddenly grew slower and only reached an 
OD600 of 0.04 on day 3. In accordance, CFU readings of day 0 and day 3 WT and 
transformant cultures revealed cell count differences of up to 1.5 fold (Figure 17). This 
was rather puzzling, as no contamination could be detected on the LB plates and the cells 
had been passaged twice prior to start of the Wayne experiment and therefore were 
expected to display similar growth dynamics. One other plausible explanation for the 
observed differences could lie with the initial inocula.   
The cultures that are distributed into the Wayne tubes have to be diluted to an 
OD600 of 0.005. This value is at the lower limit of the photospectrometer’s range and it is 
therefore possible that the initial OD600 reading was faulty, which would mean that the 
numbers of cells per tube were not the same for transformants and wild-type. It is also 
possible that the preculture that had been grown in tissue culture flasks under static 
conditions had not been mixed thoroughly enough to ensure homogeneity prior to taking 
OD600 measurements.   
Nevertheless, to counter any potential problems with the WT strain used, WT cells 




3.4.3 Colony forming units (CFU) of entC-NarK2  
Apart from the initial difference in growth rate, no disparities in OD600 development were 
observed. The growth experiments on solid medium on the other hand were able to reveal 
some phenotypic differences between transformants and wild-type BCG. Importantly, 
wild-type and transformant bacteria taken from aerobic cultures developed approximately 
the same number of visually indistinguishable colonies. However, already after seven 
days of growth in the Wayne dormancy model the EntCnar transformants developed 
much smaller colonies than wild-type BCG (Figure 15).    
 
 
Figure 15: Plates generated from seven-day-old Wayne cultures. Two WT plates on the left, two entC-
NarK2 plates on the right.  
EntC-NarK2 colonies are clearly smaller 
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This effect of reduced colony size was even more pronounced after 20 days of growth 
under anaerobic conditions (Figure 16). The Bnar transformants on the other hand, 
displayed the same size and CFU counts as wild-type BCG.  
 
Figure 16: Plates generated from 20-day-old Wayne cultures. Three WT plates in upper-half, three entC-
NarK2 plates in lower-half 
 
 
The logarithmic plot (Figure 17) shows the number of live cells present at a certain time 
during the Wayne experiment per millilitre of liquid media, as determined by counting 
colony forming units on solid medium. At every time point, apart from day 0, two Wayne 
tubes were opened for each type of bacteria. Two separate dilution series were made out 
of each tube, resulting in four plates per type and time-point. With the exception of day 0 




We observed a 100-fold drop in numbers of colonies for EntCnar transformants in 
between day seven and day 20. The numbers of viable Bnar and WT CFUs also showed a 
















Figure 17: Logarithmic plot of CFU counts for menB-NarK2, entC-NarK2 transformants and WT BCG. 
 
 
Admittedly, some cell death can be expected during transition into dormancy and is 
nothing unusual in the Wayne model, but a 10-fold decrease in CFU from day seven to 
day 20 is too high to be explained by random variation and natural death linked to the 
stress associated with hypoxia.  
Wild-type Wayne tubes displayed an uncharacteristically low OD600 value on day 
three. This could have led to slower oxygen consumption and delayed or incomplete 
transition into dormancy. If this was the cause for the reduction in WT CFU however, 
why would the Bnar cells have been affected in the exact same way? Possibly something 
was wrong with the agar used. This would however mean that all three types of cells had 
been exposed to the same irregularity. Accordingly the evident differences between WT 
and Bnar plates on one side and EntCnar plates on the other could not be ignored. It was 
reasoned that the observations made were indicative of a trend worth following up. 
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The experiment was repeated twice with EntCnar and WT only. In the follow-up 
experiments, the CFU counts of WT cells was constant from day 7 to day 20 and results 
were confirmed, insofar as the EntCnar transformants again produced colonies of much 
smaller size and in reduced numbers to WT after having been exposed to an anaerobic 















Figure 18: 10-fold Reduction of EntCnar cells between day7 and day21 based on CFU counts. (top)  
                Plates generated from 21-day-old EntCnar Wayne cultures reveal visible differences in number 
and size of colonies in comparison to WT (bottom) 
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3.4.4 ATP content of entC-NarK2 and WT 
The ATP content present in 1 ml of Wayne culture was determined with the 
BactitergloTM (Promega, USA) assay, which makes use of the light producing properties 
of the enzyme Luciferase. The amount of light produced directly depends on the amount 
of ATP present, thus allowing conclusions to be drawn on the success of inhibition of 
energy metabolism. The readout is given in Relative Luminescence Units (RLU) on a 
linear scale (Figure 19).   















Figure 19: Relative ATP content based on BactiterGloTM assay. RLU = Relative Luminescence Units 
                Error bars calculated as Standard error mean (SEM) 
 
 
It is of importance to know that this assay detects freshly produced ATP as well as 
residual ATP present in dead cells. This means that a ten-fold reduction in cell counts 
does not correspond to a tenfold reduction in RLU. Results show that samples taken from 
EntCnar cells after 20 days in the Wayne model contained approximately half the amount 
of ATP than the corresponding WT samples. The results shown here were produced with 
 53 
 
samples taken from the first experiment conducted with EntCnar cells (Figure 15, Figure 
16, Figure 17). Normally the amounts of detectable ATP increase from day 7 to day 20.  
As shown by the CFU counts of this experiment however, the numbers of WT cells 
decreased by almost 10 times in between day 7 and day 20, which might explain why 
ATP levels of the WT samples did not increase. 
 
3.5 Wayne experiments with menC-NarK2 and menD-NarK2  
A 20 day Wayne dormancy assay was set up with Cnar, Dnar and WT BCG pre-cultures. 
OD600 development of Cnar and Dnar cultures grown in the Wayne dormancy model did 















Figure 20: Wayne growth curve of Cnar, Dnar transformants 
 
Serial dilutions of Cnar and Dnar transformants produced colonies comparable to WT 
BCG in both number and size. 
Only in the period between day 15 and day 20 did numbers of Dnar colonies drop 
by about 70% and were now clearly lower than WT BCG CFU counts (Figure 21). 
Perhaps this difference would have intensified, had the assay been continued up to day 
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40. The colonies also appeared smaller now and had to be incubated a few days longer 
than the WT in order to ensure an accurate count (Figure 22).     
The differences were however far less pronounced than in the EntCnar experiments. 
 
Figure 21: CFU counts of Cnar, Dnar and WT cells on a logarithmic scale. Error bars calculated as 





Figure 22: Plates generated from 20-day-old Dnar Wayne cultures showed attenuated growth in 



















3.5.1 ATP content of menC-NarK2, menD-NarK2 and WT 
In agreement with the CFU counts, the ATP content determined by Luciferase activity, of 
Dnar day 20 samples was lower than that of Cnar day 20 samples and WT day 20 



















Figure 23: Relative ATP content based on BactiterGloTM assay. RLU = Relative Luminescence Units 




3.6 Wayne experiments with menX-2466  
 
3.6.1 Growth of menA-2466 and entC-2466 in Wayne model 
The second promoter used in these Antisense-RNA experiments was derived from the 
ORF Rv2466c, a gene of unknown function. The expression of this gene was shown to be 
upregulated during NRP2 (37), in contrast to the promoter of NarK2, which shows 
highest activity during NRP1. Consequently, the OD600 growth curves of the 
transformants were again found to follow that of the wild-type BCG cells. This time all 
OD600 values were comparable and within the expected range (Figure 24).  
menA, entC-2466


















3.6.2 CFU of menA-2466 and entC-2466  
In contrast to the experiments using the NarK2 promotor, there was no optically 
observable difference between WT plates and plates with menA:2466 and entC-2466 
transformed bacteria up to day 40. After 40 days of growth in the Wayne model, 
however, the entC-2466 plates developed a similar growth defect as the day 20 entC 
plates in the NarK2 experiments, insofar as the EntCnar colonies were of smaller size in 
comparison to WT colonies (Figure 25). This effect was not observed for any of the 
plates of menA-2466 transformants.  
 
 
Figure 25: Plates generated from 40-day-old Wayne cultures. WT on the left, F-2466 on the right.  




Based on CFU counts, the number of viable entC-2466 cells on day 40 was found to be 

















 Figure 26: Logarithmic plot of CFU counts for menA-2466 entC-2466 and WT BCG. 
 
The wild-type bacteria demonstrated a reduction of roughly 40% from day 20 to day 40, 
which is in perfect agreement with the expected development. MenA-2466 numbers only 
drop by about 20% from day 20 to day 40. As menA had been shown to be a non-essential 










3.7 Summary of CFU results 
 
Table 2 summarizes the results obtained from solid media growth experiments with 
dormant bacteria. The column labelled “Effect” refers to the observation, or lack thereof, 
of reduced numbers of colonies. The column “Essentiality” refers to the genes importance 
for survival of the bacteria as indicated by the transposon mutagenesis experiments 
performed by Sassetti et al. (42).  For strains carrying the constructs with antisense 
fragments of the genes menA, menB and menC no reduction in cell counts could be 
observed in comparison to wild-type. Bacteria carrying Antisense constructs of menD had 
slightly reduced cell counts and those carrying antisense constructs of entC displayed the 
strongest decrease in colony numbers. Interestingly, this effect was observed for both of 
the two promoters.  
 




















Table 2: Effect of different constructs on colony counts of dormant bacteria in relation to essentiality of the 
“silenced” genes as determined by transposon mutagenesis (42).   
(-) no significant reduction in CFUs observed compared to WT; (+) some reduction in CFUs observed 
compared to WT;  (++) Reduction in CFUs observed by a factor ten or more compared to WT. 
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3.8 Mass Spectrometry results 
A fixed amount of cells, determined by OD600 values, was harvested from the Wayne 
dormancy experiments. Lipids were extracted with chloroform:methanol 2:1 for analysis 
with time of flight mass spectrometry (Q-TOF MS) and quadrupole ion trap MS 
(QTRAP). Of special interest was how samples taken from different types of cells would 
compare to each other regarding their levels of menaquinones. Menaquinones can be 
divided into separate species depending on the number of isoprenic units in the backbone. 
For example, a menaquinone with five isoprenic units would be referred to as MK5. The 
Q-TOF analysis was performed in combination with a Liquid Chromatography (LC) 
column, to help separate certain menaquinone species from other lipids. Despite this 
method, none of the menaquinones could be separated clearly from other lipid groups, 
with the exception of MK9, and thus could not be quantified. MK9 levels of lipid extracts 
prepared from EntCnar day 20 cells were found to be higher than in WT day 20 cells. 
Despite large variation between samples taken from transformants, as illustrated by the 
error bar, the difference between WT and EntCnar cells seems to be significant  
(Figure 27). 


















 Figure 27: Q-TOF MK9 relative amounts. Extracts produced from day 20 cell samples.  
Each value represents an average generated from four data points, i.e. duplicates from two separate Wayne-





The QTRAP MS achieved separation of menaquinones from the other lipids of the same 
mass via a technique called Multi Reaction Monitoring (MRM), a process in which 
molecules are first filtered by mass and then fragmented to produce characteristic 
daughter ions. The measurement of a certain daughter ion allows estimates of the initial 
quantity of parent ion exposed to fragmentation (see section 2.5.2).  
The QTRAP-MRM measurements performed with two different sets of samples, confirm 
the observation made with the Q-TOF MS, that menaquinone levels differ between 
transformants and WT. A two-fold increase in MK8 levels was observed for EntCnar 
transformants in two instances, as well as for the Dnar transformants in one instance. 
EntCnar transformants displayed a 1.5-fold increase of MK9 in one experiment, but only 
a 1.2-fold gain in a second experiment (Figure 28, Figure 29). It was detected that the 
backbone of menaquinones sometimes contained a saturation of a double bond. This was 
observed for all menaquinone species studied here. The significance of this is not known. 
Interestingly, the ratio of saturated to unsaturated menaquinones is increased in dormant 
cells. Menaquinone levels from WT day 3 samples were included to illustrate this 





             
Figure 28: QTRAP-MRM (Multi Reaction Monitoring) plot of different menaquinone species present in 
lipid extracts of dormant cells (see section 2.5.2). Saturated (sat.), refers to the observation that a double 
bond in one of the isoprenic units of the backbone was saturated.  







Figure 29: QTRAP-MRM plot of different menaquinone species present in lipid extracts of dormant cells 
(see section 2.5.2). Saturated (sat.), refers to the observation that a double bond in one of the isoprenic units 
of the backbone was saturated. 

































































4.1 Rationale of this study 
It is thought that mycobacteria depend solely on menaquinone to shuttle electrons 
between respiratory complexes, whereas humans use exclusively ubiquinone for this 
purpose (56). This circumstance renders enzymes of the menaquinone synthesis pathway 
promising drug targets. In this study, we aim to elucidate if menaquinones play a crucial 
role in establishing and maintaining hypoxic dormancy, by conditionally silencing the 
translation of menaquinone synthesizing enzymes during dormancy, through the 
experimental use of antisense RNA.  
During the course of this study, a total of sixteen pJEM15 plasmids were produced. 
Each construct carried eight different antisense fragments of genes coding for the 
enzymes putatively involved in mycobacterial menaquinone synthesis. To ensure 
conditional inhibition, these antisense fragments had been linked to two distinct 
dormancy-specific promoters derived from the genes NarK2 and Rv2466c. The NarK2 
promoter exhibits peak activity during non-replicating persistence 1 (NRP1), whereas the 
Rv2466c promoter is most active during NRP2 (7, 37, 43).  
Upon transformation with these plasmid constructs, BCG cells were tested for their 
ability to induce and survive dormancy in the Wayne dormancy model system (50), in 
order to single out constructs that elicit interesting phenotypic effects. This screening 
approach was favored over a detailed examination of every construct in order to save 
time and resources. 
In a next phase of the menaquinone project, the most promising transformants will be 






4.2 Discussion of results 
In a first round of Wayne experiments conducted with six menX-NarK2 (Xnar) 
transformants, we found that the growth curve plots (OD600 vs. time) of the transformants 
closely resembled the WT plots. This suggested that the transformants were not hindered 
in their ability to replicate during early stages of the Wayne model.     
 
4.2.1 MenA- and menB-silencing showed no effect  
We went on to examine the individual transformants in more detail. The genes coding for 
the two enzymes MenA and MenB had been shown to be non-essential for aerobic 
growth (42). We wanted to investigate if this would be true for anaerobic cells as well. 
MenB has been described to be a DHNA synthase that catalyzes the formation of 1,4-
dihydroxy-2-naphthoyl-CoA from O-succinyl-benzoyl-CoA (45). The DHNA isoprenyl 
transferase MenA catalyzes the subsequent condensation reaction of the aromatic head 
group and the isoprenic backbone of menaquinone (4). Here, Wayne experiments were 
performed with menA-2466 and Bnar (menB-NarK2) transformants. We observed no 
evident growth defects on solid medium of cells taken from Wayne dormant cultures 
(Sections 3.4.3 and 3.6.2), which suggests that the two genes menB and menA are not 
only non-essential during aerobic growth as shown by Sassetti et al., 2003, but are also 





4.2.2 MenD-silencing impeded growth slightly 
The genes coding for the two enzymes MenC and MenD had been shown to be essential 
under aerobic conditions (42) This presented us with a possibility to assess the feasibility 
and efficacy of our antisense approach. MenD is the 2-succinyl-6-hydroxy-2,4-
cyclohexadiene-1-carboxylate (SHCHC) synthase that performs the second step of 
menaquinone biosynthesis. Formation of o-succinyl benzoic acid (OSB) in the 
subsequent step is performed by the OSB synthase MenC.  
Cnar transformants exhibited no reduction in colony forming units on solid 
medium, but CFU numbers of the Dnar transformants showed that the number of viable 
bacteria had clearly diminished by day 20 (section 3.5). This effect could have been 
augmented in a longer experiment of 40 days duration.   
 
4.2.3 EntC-silencing with both promoters impedes growth 
The gene entC codes for an isochorismate synthase that catalyzes the conversion of 
chorismate into isochorismate and presumably substitutes the function of MenF, which is 
absent in mycobacteria (15, 30).  
As shown in section 3.4.3, colonies of dormant cells harboring EntCnar constructs 
displayed striking growth defects in comparison to the WT, in terms of both the numbers 
and dimensions of the colonies. In fact, they were often so much smaller than the WT 
colonies that the agar plates had to be incubated up to one week longer to produce visible 
colonies.  
We speculated that the size differences could be either caused by slower growth 
rate, or by a delayed resumption of aerobic growth upon resuscitation of the 
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transformants. A delay in resumption of aerobic growth could be due to accumulated 
antisense RNA that hinders the cell in its efforts to regain all metabolic function involved 
in aerobic respiration. To test the latter hypothesis, we followed the OD development in 
tubes of resuscitated EntCnar, Bnar and WT cells in liquid media, but we were not able to 
detect any differences in OD development. Hence, it could be suggested that the defects 
only manifest when the cell has to adapt to growth on solid media. 
Transformants carrying a plasmid encoding the entC antisense construct under the 
control of the Rv2466cc promoter showed a similar phenotype after 40 days of anaerobic 
growth, supporting the hypothesis that the observed detrimental effects were due to the 
introduced antisense RNA. It needs to be mentioned, that this hypothesis will have to be 
backed up by performing control experiments with plasmids carrying scrambled or sense 
sequences of the same genes, in order to prove that the observed effects are not due to 
unspecific toxicity. Nonetheless, based on these findings, we suggest here for the first 
time that entC is indeed essential for the survival of mycobacteria during dormancy. 
 
4.2.4 ATP-quantification uncertain 
Since menaquinones are believed to be essential for mycobacterial production of energy 
equivalents via oxidative phosphorylation (45), efficient antisense inhibition of 
menaquinone production can be expected to have an effect on ATP levels.  
BactiterGloTM luciferase assays were performed with EntCnar transformants, Cnar 
transformants, Dnar transformants and WT cells, to quantify the amount of ATP present 
as a direct indication of respiratory activity. 
The BactiterGloTM luminescence intensities produced by samples prepared from the 
Cnar, Dnar Wayne experiment reflected the difference in numbers of viable cells as 
determined by the CFU counts. We were not able to determine, however, whether the 
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difference in readings was just due to the lower number of cells or if inhibition of ATP 
synthesis had occurred (Section 3.5.1). Unfortunately, the results of two independent 
experiments performed with EntCnar cells were inconclusive, possibly due to differing 
duration of storage of the cell preparations. In one case, dormant EntCnar cell 
preparations produced a luminescence signal of only half the intensity of that of dormant 
WT cells (Section 3.4.4). In samples prepared from a second experiment however, the 
luminescence intensity from dormant EntCnar cells was comparable to the luminescence 
intensity from dormant WT cell, which suggested that no difference in ATP production 
was present in the transformants (data not shown). This might indicate that a gap in the 
supply of energy equivalents might not have been the reason for the observed cell death 
of EntCnar transformants.  
 
4.2.5 Detection of menaquinones with mass spectrometry 
In order to elucidate the effects of the described antisense introduction on the 
mycobacterial menaquinone levels, the lipids from cells harboring antisense constructs 
were isolated and analyzed with two different mass spectrometers (MS). The obtained 
data indicate an increase in the range of 2-fold and 1.5-fold for MK8 and MK9 levels, 
respectively, in the dormant EntCnar transformants (Section 3.7) in comparison to WT. 
The same was found to be true for Cnar and Dnar transformants, but differences were less 
pronounced. Although at first hand these results seem to show that inhibition of entC 
translation by the introduced antisense was not successful, there are other possible 




4.2.6 Overcompensation hypothesis 
Mycobacteria possess a second enzyme capable of performing the conversion of 
chorismate into isochorismate termed MbtI (27). It has been shown recently that MbtI is 
in fact a bifunctional salicylate synthase that produces salicylate for use in mycobactin 
biosynthesis. It does this in two steps via an isochorismate intermediate (28). Even more 
recently it was shown that the main product of MbtI depends on the pH-value, with the 
main product being isochorismate at a pH-value below 7.5 and salicylate if the pH-value 
rises above 7.5. (60) 
Thus, it could be speculated that MbtI can replace the activity of EntC, that it 
further performs the isochorismate conversion with higher efficiency and that this finally 
results in increased levels of menaquinone species.  
 
4.2.7 Feedback hypothesis 
Another intriguing possibility is that mycobacteria react to the translational inhibition by 
overexpressing genes involved in menaquinone synthesis. Circumstantial evidence that 
this might be a possible scenario stems from the fact that inhibition of the respiratory 
chain in rodents treated with fibrates leads to an upregulation of enzymes involved in 
ubiquinone synthesis (1, 33, 46). Fibrates as well as menadione, an intermediate of the 
menaquinone biosynthesis pathway, and salicylate, the product of the second 
mycobacterial isochorismate utilizing enzyme MbtI, have all been shown to induce the 
expression of Rv0560c in mycobacteria (21). The observation that menadione can alter 
gene regulation presents us with the possibility that the cell can monitor the state of the 
menaquinone metabolic pathway and adapts accordingly. The gene Rv0560c clusters with 
six of the genes encoding the different MenX enzymes, and could potentially have an 
enhancing effect on their regulation. In our case, however, menadione cannot be the 
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inducing agent, since the inhibition of entC would lead to a decrease in menadione levels 
rather than an increase. 
Apart from menadione, the expression of Rv0560c can also be influenced by 
salicylate. The inducing capabilities of salicylate are of particular interest, since lack of 
EntC activity would lead to accumulation of chorismate, which could subsequently be 
converted into salicylate by MbtI, resulting in an upregulation of Rv0560c.  
It should be stressed however, that all these deliberations offer no explanation to the 
cause of the observed cell death of entC transformants upon exposure to hypoxic 
conditions. 
 
4.3 Isoprenic saturation 
While performing the MS studies we made the observation that dormant cells contained 
an increased number of menaquinones with a mass increase of two Daltons, as opposed to 
menaquinones from aerobic cells. We found that this mass increase was due to saturation 
of a double bond in the isoprenic backbone of menaquinone (data not shown). This could 
possibly be the first step of a degradation pathway as described in Nocardia (47). It might 
also be a way of altering the binding affinity of menaquinones to the respiratory 
complexes, resulting in reduced efficacy, as observed in ubiquinones (49). Another 
possibility is that the bacteria are altering their menaquinone profile upon dormancy and 
that the observed saturation is a necessary step in the shortening of the isoprenic 
backbone (11). Pursuit of this matter could lead to interesting insights on the workings of 




4.4 Future directions 
The entC antisense transformants showed promising results with regards to mycobacterial 
growth attenuation, in terms of a decrease in size and numbers, and it might be worth 
considering transformation of M. tuberculosis with entC plasmids, to determine if the 
virulence of the resulting strain is attenuated in an animal infection model system.  
A third set of MS analysis of dormant EntCnar BCG would be necessary to 
corroborate the finding that different molecular species of menaquinones show indeed 
elevated levels in these cells. A comparative microarray study could be performed, to 
examine if Rv0560c is indeed upregulated in EntCnar cells and if this results in 
differential gene expression. The theory that upregulation of menaquinone synthesis is 
linked to an increased supply of salicylate could be investigated by analysing MS profiles 
of dormant WT BCG and Rv0560c transformants upon treatment with salicylate. 
Furthermore, a fibrate sensitivity test of the Rv0560c transformants could yield 
interesting results (21). 
There are several pitfalls associated with the use of antisense RNA. One difficulty 
lies in the tendency of RNA to develop secondary structures as opposed to DNA, due to 
its greater flexibility in the sugar-phosphate backbone. This might compromise the 
antisense RNA’s capability of binding to its mRNA counterpart, or worse, make it 
interact with unspecific targets and lead to unforeseen events.  
Moreover, according to the theory of tight coupling of transcription with 
translation in bacteria (22), it is difficult to imagine efficient binding of antisense RNA to 
the nascent mRNA strand in the presence of the ribosome.  
Thus, the correct functioning of the antisense inhibition mechanism should be 
verified for all transformants produced in the course of this study. To this end, Northern 
blots could be performed to confirm the presence of antisense RNA in the first place. 
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Additionally or alternatively one could carry out qRT-PCR assays to test if levels of 
target mRNA are diminished. In a second step, Western blots could be used to investigate 
if concentrations of the targeted proteins are indeed reduced. Further, one could explore 
the possibility of detecting intermediates of the menaquinone biosynthesis pathway with 





























We successfully generated sixteen BCG transformants harbouring antisense constructs of 
genes putatively involved in menaquinone metabolism under control of two dormancy-
specific promoters.  
Six of these sixteen BCG transformants were used for Wayne dormancy 
experiments, and of these six, three were found to exhibit growth defects when taken 
from an anaerobic environment and spread on solid media. We suggest here that these 
transformants were compromised in their ability to establish persistence successfully. 
However, we were not able to link the observed growth defects to a lack of 
menaquinones and subsequent failure to produce ATP. Further follow-up studies as well 
as examination of the remaining ten transformants is needed to clarify these observations.  
The transformants generated in the course of this study provide a foundation for a 
number of further projects that could significantly contribute to the knowledge of 
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Shown here are the sequences of eight expression vectors sequenced by Research Biolabs 
technologies pte. ltd. (Singapore), with an ABI PRISM 3100 capillary sequencer 
(Applied Biosystems, USA).  
One example of each insert is given. The first vector encodes the Rv2466c 
promoter sequence, the seven following vectors encode the NarK2 promoter sequence.  
Sequencing was performed using reverse primer and forward primer. Since the forward 
primer did not perform well, its results are not included. Reverse sequences depicted here 
were converted into their complementary strands, to show the promoter in sense and the 
insert in antisense orientation.  
The quality of sequencing of the promoter regions was relatively poor, as they 




Rv2466c-anti-menA construct (Rv0534c) 
 
5’GNGATCNANTCANNGAGACTTTNTAATTTTTATAATAATGGGACCTANGTNCCTTTTT 





















NarK2-anti-menB construct (Rv0548c) 
 





















NarK2-anti-menC construct (Rv0553) 
 






















NarK2-anti-menD construct (Rv0555) 
 
5’GGGANCCTAAAGTTCCCTTTTTTATTTAAAAATTTTTTCCAAAAACGNTTACAAGCAT 






















NarK2-anti-menE construct (Rv0542c) 
 





















NarK2-anti-entC construct (Rv3215) 
 























NarK2-anti-menH construct (Rv0558) 
 
5’ TAATTAATTGGGGACCCTAGAGGTCCCCTTTTTTATTTTAAAAATTTTTTCACAA 

























     sph1   antisense-Rv0560c → 
CTGGGCCCGCGGATCC_GCATGC_CCAACACGAAGTAGGAGGCGCCCGGTGCCGCCGCAC
GCACGATCGATTGCAGATCGCCCTCCCGGGACTCGACCGGCATGGAGTGGAACAGTGTGC
TGTCGACGATGGTGTCGAACCTGCCGTCATAGCCGGTAAACGAACTGGCGTCGGCCACCT
CGAAGCTGGCATTGGCCAGGCCGCGCTTCGCTGCTTCATGCCGAGCCAGTTCTACGGCGG
CGGGGGAGAGGTCCAGTCCGACCGTGGTGTGTCCCCGTTCGGCCAGTGCCAGCGAAATCG
CGGCCTCCCCGCAGCCCACGTCGAGGACGTCGCCGCGGAACTTGCCCTGCACGAACAGGG
CGGCCAGCTCGGGCTGGGGTTCGCCGATGCTCCATGGCGGTCGGACTCCCTCCCCGAAGG
CGACGGATTCACCGCGGTAGGCGGATTCGAACTCAAGATCCAGCGATTCAGTCATGTGTT
CATATATATCAACGGCCCTGATATATGTCAACACAGTTGACATTCGCGCACCCTTGGTTG
CCGGCCGTCAGCTGAACGGCGGTCGTCGATCGACGAGCCGGGACAATTGACCGCCACCGC 
GCCACACCCGCGCCACCCAGTCGCGGTCGTCGTCGGTGACCAGATTGGACATCACCCGCA 
kpn1 
_GGTACC_AAGCNTGATCCGATAACACAGAACAGATTTA 
 
